CR20110118A - Tratamiento de enfermedades autoinmunes e inflamatorias - Google Patents
Tratamiento de enfermedades autoinmunes e inflamatoriasInfo
- Publication number
- CR20110118A CR20110118A CR20110118A CR20110118A CR20110118A CR 20110118 A CR20110118 A CR 20110118A CR 20110118 A CR20110118 A CR 20110118A CR 20110118 A CR20110118 A CR 20110118A CR 20110118 A CR20110118 A CR 20110118A
- Authority
- CR
- Costa Rica
- Prior art keywords
- treatment
- autoimmune
- inflammatory diseases
- biological activity
- multiple sclerosis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Psychiatry (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención proporciona nuevos procedimientos de tratamiento de la esclerosis múltiple y otras enfermedades autoinmunitarias o trastornos inflamatorios, y antagonistas, que incluyen proteínas de unión aisladas para su uso en los nuevos procedimientos. Se proporciona un procedimiento de tratamiento de la esclerosis múltiple que comprende la neutralización de la actividad biológica de la IL-7 mediante la unión a CD127 o a IL-7. Las proteínas de unión aisladas también pueden neutralizar la actividad biológica de la TSLP.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8729408P | 2008-08-08 | 2008-08-08 | |
US16980109P | 2009-04-16 | 2009-04-16 | |
US21862709P | 2009-06-19 | 2009-06-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20110118A true CR20110118A (es) | 2011-07-28 |
Family
ID=41382165
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20110118A CR20110118A (es) | 2008-08-08 | 2011-03-03 | Tratamiento de enfermedades autoinmunes e inflamatorias |
Country Status (23)
Country | Link |
---|---|
US (2) | US20110287000A1 (es) |
EP (1) | EP2318442A1 (es) |
JP (1) | JP2011530533A (es) |
KR (1) | KR20110044777A (es) |
CN (1) | CN102177179A (es) |
AR (1) | AR072985A1 (es) |
AU (1) | AU2009279471A1 (es) |
BR (1) | BRPI0916945A2 (es) |
CA (1) | CA2733432A1 (es) |
CL (1) | CL2011000269A1 (es) |
CO (1) | CO6341640A2 (es) |
CR (1) | CR20110118A (es) |
DO (1) | DOP2011000041A (es) |
EA (1) | EA201100150A1 (es) |
IL (1) | IL211034A0 (es) |
MA (1) | MA32621B1 (es) |
MX (1) | MX2011001477A (es) |
NZ (1) | NZ590994A (es) |
PE (1) | PE20110382A1 (es) |
TW (1) | TW201018482A (es) |
UY (1) | UY32038A (es) |
WO (1) | WO2010017468A1 (es) |
ZA (1) | ZA201100974B (es) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8171134B2 (en) * | 2009-03-18 | 2012-05-01 | At&T Intellectual Property I, L.P. | Methods and apparatus to characterize and predict network health status |
JP5850860B2 (ja) | 2010-01-28 | 2016-02-03 | グラクソ グループ リミテッドGlaxo Group Limited | Cd127結合タンパク質 |
WO2011100567A1 (en) * | 2010-02-11 | 2011-08-18 | The Board Of Trustees Of The Leland Stanford Junior University | Therapeutic inhibition of granulocyte function in demyelinating disease |
AU2014201648B2 (en) * | 2010-02-24 | 2016-05-12 | Rinat Neuroscience Corp. | Antagonist anti-il-7 receptor antibodies and methods |
TWI552760B (zh) | 2010-02-24 | 2016-10-11 | 雷那特神經科學股份有限公司 | 拮抗劑抗-il-7受體抗體及方法 |
US8858944B2 (en) | 2010-06-02 | 2014-10-14 | Sumitomo Dainippon Pharma Co., Ltd. | Treatment drug for autoimmune diseases and allergic diseases |
US20130295111A1 (en) * | 2010-08-10 | 2013-11-07 | The Scripps Research Institute | Methods and compositions for treating disorders associated with hyperactive immune system |
US9217040B2 (en) | 2011-01-14 | 2015-12-22 | The Regents Of The University Of California | Therapeutic antibodies against ROR-1 protein and methods for use of same |
EP2583980A1 (en) | 2011-10-19 | 2013-04-24 | Effimune | Antibodies directed against the alpha chain of IL7 receptor - their use for the preparation of drug candidates |
FR2988479B1 (fr) * | 2012-03-23 | 2014-12-19 | Hospices Civils Lyon | Procede de determination de la susceptibilite aux infections nosocomiales |
US9789169B2 (en) * | 2014-04-29 | 2017-10-17 | Bio-Cancer Treatment International Limited | Methods and compositions for modulating the immune system with arginase I |
EP2955196A1 (en) * | 2014-06-10 | 2015-12-16 | Effimune | Antibodies directed against CD127 |
WO2016044189A1 (en) * | 2014-09-15 | 2016-03-24 | Genentech, Inc. | Methods of treating cancer using pd-1 axis binding antagonist and il-17 binding antagonists |
WO2016059512A1 (en) | 2014-10-18 | 2016-04-21 | Pfizer Inc. | Anti-il-7r antibody compositions |
US20160264658A1 (en) * | 2015-03-11 | 2016-09-15 | Glaxosmithkline Intellectual Property Development Limited | TSLP Binding Proteins |
WO2017055966A1 (en) | 2015-10-01 | 2017-04-06 | Pfizer Inc. | Low viscosity antibody compositions |
US10392441B2 (en) | 2015-10-07 | 2019-08-27 | United States Of America, As Represented By The Secretary, Department Of Health And Human Services | IL-7R-alpha specific antibodies for treating acute lymphoblastic leukemia |
ES2737307T3 (es) | 2016-02-29 | 2020-01-13 | Ose Immunotherapeutics | Anticuerpos no antagonistas dirigidos contra la cadena alfa del dominio extracelular del receptor de IL7 y uso del mismo en el tratamiento del cáncer |
NZ753213A (en) * | 2016-12-09 | 2022-05-27 | Ose Immunotherapeutics | Antibodies and polypeptides directed against cd127 |
JOP20190243A1 (ar) | 2017-04-12 | 2019-10-13 | Medimmune Llc | علاج الربو بجسم مضاد لـ tslp |
SG11202107951YA (en) * | 2019-01-22 | 2021-08-30 | Bristol Myers Squibb Co | Antibodies against il-7r alpha subunit and uses thereof |
CN117343173A (zh) * | 2019-03-07 | 2024-01-05 | 瑞阳(苏州)生物科技有限公司 | 人IL-1β蛋白结合分子及其编码基因和应用 |
TW202140550A (zh) | 2020-01-29 | 2021-11-01 | 瑞士商諾華公司 | 使用抗tslp抗體治療炎性或阻塞性氣道疾病之方法 |
JP2023513312A (ja) | 2020-02-13 | 2023-03-30 | アムジェン インコーポレイテッド | ヒト抗tslp抗体の製剤及び炎症性疾患を治療する方法 |
WO2021163588A1 (en) | 2020-02-13 | 2021-08-19 | Amgen Inc. | Treatment of atopic dermatitis with anti-tslp antibody |
AR121368A1 (es) | 2020-02-18 | 2022-06-01 | Amgen Inc | Formulaciones de anticuerpos anti-tslp humanos y métodos de uso de los mismos |
AR124286A1 (es) | 2020-12-02 | 2023-03-15 | Glaxosmithkline Ip Dev Ltd | Proteínas de unión a il-7 y su uso en tratamientos médicos |
WO2023227641A1 (en) | 2022-05-27 | 2023-11-30 | Glaxosmithkline Intellectual Property Development Limited | Use of tnf-alpha binding proteins and il-7 binding proteins in medical treatment |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5194375A (en) * | 1989-06-15 | 1993-03-16 | Immunex Corporation | Dna encoding interleukin-7 receptors and methods of use |
US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
EP0667395A4 (en) * | 1993-06-01 | 1996-07-03 | Toray Industries | MONOCLONAL ANTIBODIES, APPLICATION AND PRODUCTION METHOD. |
US20050054054A1 (en) * | 2002-11-12 | 2005-03-10 | Foss Francine M. | Interleukin-7 molecules with altered biological properties |
WO2005123774A2 (en) * | 2004-06-15 | 2005-12-29 | Erol Fikrig | Antibodies to west nile virus polypeptides |
WO2006052660A2 (en) * | 2004-11-04 | 2006-05-18 | Childrens Hospital Los Angeles Research Institute | Il-7 receptor blockade to suppress immunity |
JP2008532936A (ja) * | 2005-02-14 | 2008-08-21 | ワイス | インターロイキン−17f抗体及び他のil−17fシグナル伝達拮抗物質並びにそれらの使用 |
CA2513350A1 (en) * | 2005-03-02 | 2006-09-02 | Sydney West Area Health Service | Treatment for multiple sclerosis |
GB2434578A (en) * | 2006-01-26 | 2007-08-01 | Univ Basel | Transgenic animals |
-
2009
- 2009-08-06 UY UY0001032038A patent/UY32038A/es unknown
- 2009-08-06 TW TW098126600A patent/TW201018482A/zh unknown
- 2009-08-07 KR KR1020117005442A patent/KR20110044777A/ko not_active Application Discontinuation
- 2009-08-07 BR BRPI0916945A patent/BRPI0916945A2/pt not_active IP Right Cessation
- 2009-08-07 WO PCT/US2009/053136 patent/WO2010017468A1/en active Application Filing
- 2009-08-07 MX MX2011001477A patent/MX2011001477A/es unknown
- 2009-08-07 AR ARP090103039A patent/AR072985A1/es unknown
- 2009-08-07 US US13/057,893 patent/US20110287000A1/en not_active Abandoned
- 2009-08-07 PE PE2011000140A patent/PE20110382A1/es not_active Application Discontinuation
- 2009-08-07 NZ NZ590994A patent/NZ590994A/xx not_active IP Right Cessation
- 2009-08-07 CA CA2733432A patent/CA2733432A1/en not_active Abandoned
- 2009-08-07 AU AU2009279471A patent/AU2009279471A1/en not_active Abandoned
- 2009-08-07 EP EP09791287A patent/EP2318442A1/en not_active Withdrawn
- 2009-08-07 US US12/537,705 patent/US20100040616A1/en not_active Abandoned
- 2009-08-07 JP JP2011522273A patent/JP2011530533A/ja not_active Withdrawn
- 2009-08-07 CN CN2009801397595A patent/CN102177179A/zh not_active Withdrawn
- 2009-08-07 EA EA201100150A patent/EA201100150A1/ru unknown
-
2011
- 2011-02-02 DO DO2011000041A patent/DOP2011000041A/es unknown
- 2011-02-03 IL IL211034A patent/IL211034A0/en unknown
- 2011-02-07 ZA ZA2011/00974A patent/ZA201100974B/en unknown
- 2011-02-08 CL CL2011000269A patent/CL2011000269A1/es unknown
- 2011-02-11 CO CO11016609A patent/CO6341640A2/es unknown
- 2011-03-03 CR CR20110118A patent/CR20110118A/es not_active Application Discontinuation
- 2011-03-08 MA MA33682A patent/MA32621B1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
EP2318442A1 (en) | 2011-05-11 |
MA32621B1 (fr) | 2011-09-01 |
EA201100150A1 (ru) | 2011-10-31 |
JP2011530533A (ja) | 2011-12-22 |
MX2011001477A (es) | 2011-03-25 |
BRPI0916945A2 (pt) | 2015-11-24 |
DOP2011000041A (es) | 2011-02-28 |
CL2011000269A1 (es) | 2012-07-20 |
NZ590994A (en) | 2012-09-28 |
CO6341640A2 (es) | 2011-11-21 |
WO2010017468A1 (en) | 2010-02-11 |
US20100040616A1 (en) | 2010-02-18 |
CN102177179A (zh) | 2011-09-07 |
KR20110044777A (ko) | 2011-04-29 |
AR072985A1 (es) | 2010-10-06 |
TW201018482A (en) | 2010-05-16 |
UY32038A (es) | 2010-03-26 |
US20110287000A1 (en) | 2011-11-24 |
IL211034A0 (en) | 2011-04-28 |
AU2009279471A1 (en) | 2010-02-11 |
ZA201100974B (en) | 2012-10-31 |
PE20110382A1 (es) | 2011-06-27 |
CA2733432A1 (en) | 2010-02-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR20110118A (es) | Tratamiento de enfermedades autoinmunes e inflamatorias | |
ECSP12012211A (es) | Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf) | |
ECSP077280A (es) | Moduladores de quinasa de pirrolo-piridina | |
CR20120248A (es) | Inmunoglobulinas con dominio variable dual y usos de las mismas | |
EA201370081A1 (ru) | Антитела к cd48 и их применение | |
UY32808A (es) | Inmunoglobulinas como dominio variable dual y usos de las mismas | |
CL2014003110A1 (es) | Anticuerpo anti-fcrn; secuencias que lo codifican; vector; célula huésped; proceso de producción; composición farmacéutica que lo comprende; uso para el tratamiento de enfermedad autoinmune; y ensayo para probar la capacidad de un anticuerpo para bloquear la actividad de fcrn humano. | |
CO6592067A2 (es) | Proteinas de elance a cd 127 | |
TW200745109A (en) | Pyrrolo-pyridine kinase modulators | |
BR112012009846B8 (pt) | método in vitro e kit para detecção de um anticorpo antifármaco de isotipo ige, e uso de um anticorpo antifármaco de isotipo ige no tratamento de distúrbio mediado por ige | |
EA202090031A3 (ru) | Человеческие антитела против gfr3 и способы их применения | |
UA107812C2 (en) | Oktahidropirolo disubstituted [3,4-c] pyrrole receptors as orexin modulators | |
EA200901621A1 (ru) | Индукция толерогенного фенотипа у зрелых дендритных клеток | |
ECSP088751A (es) | Anticuerpos contra la il-22 humana y usos para los mismos | |
ECSP13012402A (es) | Inmunoglobulinas con dominio variable dual y su uso | |
EA201390711A1 (ru) | Гидроксиамидные соединения пиримидина в качестве ингибиторов деацетилаз белков и способы их применения | |
EA201390669A1 (ru) | Способы и композиции для иммунотерапии заболеваний нервной системы | |
CO6531489A2 (es) | Anticuerpo anti -tslp modificado por técnicas de ingenieria genética | |
EP2563794A4 (en) | INHIBITORS OF TYROSINE KINASE PROTEIN ACTIVITY AND THEIR APPLICATIONS TO THE TREATMENT OF OPHTHALMIC DISORDERS | |
ECSP13012536A (es) | Composiciones de anticuerpo y métodos de uso | |
BR112014000634A2 (pt) | métodos para tratamento de incontinência associada com atividade sexual | |
UY33662A (es) | Combinaciones que comprenden inhibidores de dhodh e inhibidores de cox | |
ATE489947T1 (de) | Axomadol zur schmerzbehandlung bei arthrose | |
ES2586805T3 (es) | Análogos de péptidos para tratar enfermedades y trastornos | |
ECSP056015A (es) | Anticuerpos contra el receptor de il-21 humano y usos de los mismos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal (granting procedure) |